Home / Health / Ebola Drug Sparks Hope: Island Pharma Soars 47%
Ebola Drug Sparks Hope: Island Pharma Soars 47%
7 Jul
Summary
- Island Pharmaceuticals' experimental drug galidesivir approved for Ebola.
- Drug approved for emergency use against Bundibugyo Ebola strain.
- Company shares surged by as much as 47% on the news.
Island Pharmaceuticals Ltd. experienced a significant market reaction, with its stock climbing as much as 47%. This surge followed the announcement that the company's experimental antiviral medication, galidesivir, has successfully obtained both regulatory and ethics approvals.
The approvals are for the emergency use of galidesivir in Uganda. Specifically, the drug is designated to treat patients diagnosed with the Bundibugyo strain of the Ebola virus.
Galidesivir is an intravenous medication. Its design is focused on combating the effects of the Ebola virus within infected individuals. The approvals mark a critical step in potentially deploying this treatment.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
